Publications
Detailed Information
Antiviral efficacy of combination therapy with entecavir and adefovir for entecavir/lamivudine-resistant hepatitis B virus with or without adefovir resistance
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yang, Hyo-Joon | - |
dc.contributor.author | Lee, Jeong-Hoon | - |
dc.contributor.author | Kim, Yoon Jun | - |
dc.contributor.author | Yoon, Jung-Hwan | - |
dc.contributor.author | Lee, Hyo-Suk | - |
dc.creator | 윤정환 | - |
dc.date.accessioned | 2013-03-29T04:17:11Z | - |
dc.date.available | 2013-03-29T04:17:11Z | - |
dc.date.issued | 2012-09 | - |
dc.identifier.citation | JOURNAL OF MEDICAL VIROLOGY Vol.84 No.3, pp. 424-430 | - |
dc.identifier.issn | 0146-6615 | - |
dc.identifier.uri | https://hdl.handle.net/10371/81537 | - |
dc.description.abstract | There is little clinical information on the management of hepatitis B virus (HBV) that is resistant to multiple drugs including entecavir (ETV). The present retrospective cohort study assessed the antiviral efficacy of ETV/adefovir dipivoxil (ADV) combination therapy for ETV-resistant HBV with prior lamivudine (LAM) resistance, and either with or without previous ADV resistance. The cumulative probability of achieving a virological response (undetectable serum HBV DNA) was compared by KaplanMeier analysis and the Breslow method. Seventeen patients with ETV-resistant HBV who were treated with ETV/ADV combination therapy for at least 6 months at a tertiary care center, were included; seven had dual resistance to ETV and LAM [ADV-r(-) group] and 10 had triple resistance to ETV, LAM, and ADV [ADV-r(+) group]. The median follow-up period was 9 months (range, 623). A virological response was noted in seven patients after a median of 3 months (range, 312) of treatment; five in the ADV-r(-) group and two in the ADV-r(+) group. The cumulative probability of a virological response was significantly higher in the ADV-r(-) group than in the ADV-r(+) group (6 months cumulative probability, 57.1% vs. 11.1%). In conclusion, ETV/ADV combination therapy led to virological responses in five of seven patients with resistance to ETV and LAM, but a significantly poorer response in patients with prior ADV resistance than in those without prior ADV resistance. Therefore, ETV/ADV combination therapy could be a useful therapeutic option for ETV- and LAM-resistant HBV without prior ADV resistance. J. Med. Virol. 84:424430, 2012. (C) 2011 Wiley Periodicals, Inc. | en |
dc.language.iso | en | en |
dc.publisher | WILEY-LISS | en |
dc.subject | 복합학 | en |
dc.subject | entecavir resistance | - |
dc.subject | multidrug resistance | - |
dc.subject | rescue therapy | - |
dc.subject | chronic hepatitis B | - |
dc.title | Antiviral efficacy of combination therapy with entecavir and adefovir for entecavir/lamivudine-resistant hepatitis B virus with or without adefovir resistance | en |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 양효준 | - |
dc.contributor.AlternativeAuthor | 이정훈 | - |
dc.contributor.AlternativeAuthor | 김윤준 | - |
dc.contributor.AlternativeAuthor | 윤정환 | - |
dc.contributor.AlternativeAuthor | 이효석 | - |
dc.identifier.doi | 10.1002/jmv.23229 | - |
dc.description.srnd | OAIID:oai:osos.snu.ac.kr:snu2012-01/102/0000027897/10 | - |
dc.description.srnd | SEQ:10 | - |
dc.description.srnd | PERF_CD:SNU2012-01 | - |
dc.description.srnd | EVAL_ITEM_CD:102 | - |
dc.description.srnd | USER_ID:0000027897 | - |
dc.description.srnd | ADJUST_YN:Y | - |
dc.description.srnd | EMP_ID:A078509 | - |
dc.description.srnd | DEPT_CD:801 | - |
dc.description.srnd | CITE_RATE:2.82 | - |
dc.description.srnd | FILENAME:10.pdf | - |
dc.description.srnd | DEPT_NM:의학과 | - |
dc.description.srnd | EMAIL:yoonjh@snu.ac.kr | - |
dc.description.srnd | SCOPUS_YN:Y | - |
dc.description.srnd | CONFIRM:Y | - |
dc.identifier.srnd | 2012-01/102/0000027897/10 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.